MET inhibitors as salvage therapy for MET-amplified gastric cancer with pulmonary lymphangitis

Xiufeng Zheng; Mo Cheng; Wenke Li; Ming Liu

doi:10.1093/pcmedi/pbae035

Precision Clinical Medicine ›› 2025, Vol. 8 ›› Issue (1) :pbae035 DOI: 10.1093/pcmedi/pbae035

Correspondence

research-article

MET inhibitors as salvage therapy for MET-amplified gastric cancer with pulmonary lymphangitis

Xiufeng Zheng ¹^,²^,^‡
, Mo Cheng ²^,^‡
, Wenke Li ²
, Ming Liu ²^,^*

Author information +

History +

PDF (344KB)

Cite this article

Download citation ▾

Xiufeng Zheng, Mo Cheng, Wenke Li, Ming Liu. MET inhibitors as salvage therapy for MET-amplified gastric cancer with pulmonary lymphangitis. Precision Clinical Medicine, 2025, 8(1): pbae035 DOI:10.1093/pcmedi/pbae035

登录浏览全文

4963

注册一个新账户忘记密码

Acknowledgements

This work was supported by the Sichuan Science and Technology Program (Grant No. 23ZDYF2874), and the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (Grant No. ZYJC21043).

Author contributions

Xiufeng Zheng (Data curation, Formal analysis, Investigation, Writing—original draft), Mo Cheng (Data curation, Formal analysis, Writing—original draft), Wenke Li (Data curation), and Ming Liu (Funding acquisition, Supervision)

Conflict of interest

None declared.

Ethics

The study was approved by the Hospital Ethics Committee of West China Hospital, Sichuan University, and the need for written informed consent was waived.

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Mo MH, Liu P. Targeting MET in cancer therapy. Chronic Dis Transl Med 2017;3:148-53. https://doi.org/10.1016/j.cdtm.2017.06.002

[2]	Klimek M. Pulmonary lymphangitis carcinomatosis: systematic review and meta-analysis of case reports, 1970-2018. Postgrad Med 2019;131:309-18. https://doi.org/10.1080/00325481.2019.1595982.

[3]	Zhang Z, Yu Y, Xie T et al. Pulmonary lymphangitis carcinomatosis: A peculiar presentation clustering in MET-amplified gastric cancer. Cancer Med 2023;12:19583-94. https://doi.org/10.1002/cam4.6575.

[4]

Yu Y, Guo Q, Zhang Y et al. Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study. The Lancet Respiratory Medicine 2024;12:958-66. https://doi.org/10.1016/S2213-2600(24)00211-X.

[5]	Chaudhary SP, Kwak EL, Hwang KL et al. Revisiting MET: clinical characteristics and treatment outcomes of patients with locally advanced or metastatic, MET-amplified esophagogastric cancers. Oncologist 2020;25:e1691-700. https://doi.org/10.1634/ theoncologist.2020-0274.

[6]	Wolf J, Seto T, Han J-Y et al. Capmatinib in MET exon 14mutated or MET-amplified non-small-cell lung cancer. N Engl J Med 2020;383:944-57. https://doi.org/10.1056/NEJMoa2002787.

[7]	Peng L-X, Jie G-L, Li A-N et al. MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors. Experimental Hematology & Oncology 2021;10:52. https://doi.org/10.1186/s40164-021-00245-y.

[8]	Shah MA, Cho J-Y, Tan IB et al. A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junction. Oncologist 2016;21:1085-90. https://doi.org/10.1634/th eoncologist.2016-0038.

[9]	Van Cutsem E, Karaszewska B, Kang YK et al. A multicenter phase II study of AMG 337 in patients with METamplified gastric/gastroesophageal junction/esophageal adenocarcinoma and other MET-amplified solid tumors. Clin Cancer Res 2019;25:2414-23. https://doi.org/10.1158/1078-0432.CCR-18 -1337.

[10]	Zhang YF, Shen L, Peng Z. Advances in MET tyrosine kinase inhibitors in gastric cancer. Cancer Biol Med 2024;21:484-98. https://doi.org/10.20892/j.issn.2095-3941.2024.0044